World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
50887
World Ranking
13386
National Ranking
6808

Michael Boyer publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Michael Boyer sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 450 publications — 49th percentile

49% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Michael Boyer D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Michael Boyer sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Michael Boyer is affiliated with the University of Utah in the United States. Their research spans primarily the fields of Medicine and Biochemistry, Genetics, and Molecular Biology, with a focus on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Immunology, and Cancer Research.

The main topics of Boyer's work include:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer therapeutics and mechanisms
  • Cancer Genomics and Diagnostics
  • Colorectal Cancer Treatments and Studies

Boyer has a substantial publication record, including contributions to frequent publication venues such as:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Annals of Oncology
  • Cancer Research
  • Regular and Young Investigator Award Abstracts

Some of the recent papers by Boyer are:

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer, 2020, Journal of Clinical Oncology
  • Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189, 2021, Annals of Oncology
  • The James Webb Space Telescope Mission, 2023, Publications of the Astronomical Society of the Pacific
  • Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1-Positive Advanced NSCLC, 2021, Journal of Thoracic Oncology
  • Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial, 2022, Journal of Clinical Oncology

Boyer frequently collaborates with several researchers, including:

  • Enriqueta Felip
  • Jenny Lee
  • Steven Kao
  • Shirish M. Gadgeel
  • Delvys Rodríguez-Abreu

Best Publications

  • Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

    Leena Gandhi;Delvys Rodríguez-Abreu;Shirish Gadgeel;Emilio Esteban

  • Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    S. L. Maude;Theodore W Laetsch;J. Buechner;S. Rives

  • Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

    Lecia V. Sequist;James Chih-Hsin Yang;Nobuyuki Yamamoto;Kenneth John O'Byrne

  • Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma

    Nicholas J. Vogelzang;James J. Rusthoven;James Symanowski;Claude Denham

  • Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048) : a randomised, open-label, phase 3 study

    Barbara Burtness;Kevin J. Harrington;Richard Greil;Denis Soulières

  • The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients

    Jean Klastersky;Marianne Paesmans;Edward B. Rubenstein;Michael Boyer

  • Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

    James Chih Hsin Yang;Yi Long Wu;Martin Schuler;Martin Sebastian

  • Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

    Eric Van Cutsem;Chris Twelves;Jim Cassidy;David Allman

  • Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

    Keunchil Park;Eng Huat Tan;Ken O'Byrne;Li Zhang

  • Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.

    Shirish Gadgeel;Delvys Rodríguez-Abreu;Giovanna Speranza;Emilio Esteban

  • The dynamics of change: Cancer patients' preferences for information, involvement and support

    P. N. Butow;M. Maclean;S. M. Dunn;M. H. N. Tattersall

  • First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin

    J. Cassidy;C. Twelves;E. Van Cutsem;P. Hoff

  • Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study

    Nico van Zandwijk;Nick Pavlakis;Steven C Kao;Anthony Linton

  • Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia

    Elena J. Orlando;Xia Han;Catherine Tribouley;Patricia A. Wood

  • Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.

    L. Paz-Ares;E. H. Tan;K. O'Byrne;L. Zhang

  • Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer

    Suresh S. Ramalingam;Fiona Blackhall;Maciej Krzakowski;Carlos H. Barrios

  • Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group

    J von Pawel;R von Roemeling;U Gatzemeier;M Boyer

  • High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy

    Steven C.H. Kao;Nick Pavlakis;Rozelle Harvie;Janette L. Vardy

  • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.

    Robert J. Soiffer;Haesook T. Kim;Joseph McGuirk;Mitchell E. Horwitz

  • The M ultinational A ssociation f or S upportive C are i n Cancer R isk I ndex: A M ultinational S coring S ystem f or Identifying L ow-Risk F ebrile N eutropenic C ancer P atients

    Jean Klastersky;Marianne Paesmans;Edward B. Rubenstein;Michael Boyer

Frequent Co-Authors

Stephen J. Clarke
Stephen J. Clarke University of Sydney
Kenneth J. O'Byrne
Kenneth J. O'Byrne Queensland University of Technology
Tony Mok
Tony Mok Chinese University of Hong Kong
Stephan A. Grupp
Stephan A. Grupp Children's Hospital of Philadelphia
Luis Paz-Ares
Luis Paz-Ares Complutense University of Madrid
Michael A. Pulsipher
Michael A. Pulsipher University of Utah
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University
James Chih-Hsin Yang
James Chih-Hsin Yang National Taiwan University
Edward B. Garon
Edward B. Garon University of California, Los Angeles
Martin H.N. Tattersall
Martin H.N. Tattersall University of Sydney

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens up many paths beyond the traditional MD route. For those interested in leadership or administration, a healthcare administration degree online accredited program offers flexibility and specialized training for managing healthcare organizations. These accredited online degrees allow students to balance their studies with professional or personal obligations.

Aspiring nurse practitioners may consider asn to fnp programs. These bridge programs are designed for registered nurses who want to advance their clinical knowledge and become Family Nurse Practitioners, opening doors to higher-level patient care roles.

Nutrition is another essential part of healthcare. An increasing number of students are enrolling in online nutrition degree programs to gain the expertise needed for clinical, public health, and wellness careers.

For those seeking advanced administrative or executive roles, cahme accredited online healthcare administration programs provide a rigorous, industry-recognized curriculum entirely online. These diverse degree options expand opportunities for anyone passionate about healthcare, whether in direct patient care, management, or allied fields.

Best Scientists Citing Michael Boyer

Trending Scientists

Recently Published Articles